Comparative Pharmacology
Head-to-head clinical analysis: AZULFIDINE versus LIALDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZULFIDINE versus LIALDA.
AZULFIDINE vs LIALDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfasalazine is a prodrug that is cleaved by gut bacteria to form 5-aminosalicylic acid (5-ASA) and sulfapyridine. 5-ASA acts locally in the colon to reduce inflammation by inhibiting prostaglandin synthesis and leukotriene formation, antioxidant effects, and inhibition of cytokine production. Sulfapyridine provides additional immunosuppressive effects.
Mesalamine, the active ingredient in Lialda, is an anti-inflammatory agent that inhibits prostaglandin production and leukotriene synthesis, and reduces cytokine production in the colonic mucosa.
Oral, 500 mg to 1 g twice daily, initially 500 mg twice daily, increase to 1 g twice daily after 1 week if tolerated; maximum 3 g/day.
2-4 tablets (2.4-4.8 g) orally once daily. Each tablet contains 1.2 g mesalamine.
None Documented
None Documented
Sulfapyridine: 10-14 hours; 5-ASA: 0.6-1.4 hours (rapid acetylation). Clinical context: Twice-daily dosing maintains therapeutic sulfapyridine levels.
Terminal elimination half-life of mesalamine is approximately 12 hours (range 8-15 hours) for the sustained-release formulation; clinical steady-state is reached within 3-5 days.
Renal: 75% (sulfapyridine metabolites), 15% (5-aminosalicylic acid). Biliary/fecal: 10%.
Renal (primarily, as N-acetyl-5-aminosalicylic acid, about 80%) and fecal (as unchanged mesalamine, about 20%).
Category C
Category C
Aminosalicylate
Aminosalicylate